TY - JOUR
T1 - Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
AU - Dummer, Reinhard
AU - Hauschild, Axel
AU - Santinami, Mario
AU - Atkinson, Victoria
AU - Mandalà, Mario
AU - Kirkwood, John M.
AU - Chiarion Sileni, Vanna
AU - Larkin, James
AU - Nyakas, Marta
AU - Dutriaux, Caroline
AU - Haydon, Andrew
AU - Robert, Caroline
AU - Mortier, Laurent
AU - Schachter, Jacob
AU - Lesimple, Thierry
AU - Plummer, Ruth
AU - Dasgupta, Kohinoor
AU - Gasal, Eduard
AU - Tan, Monique
AU - Long, Georgina V.
AU - Schadendorf, Dirk
N1 - Place: United States
PY - 2020/9/1
Y1 - 2020/9/1
N2 - BACKGROUND: In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations. To confirm the stability of the relapse-free survival benefit, longer-term data were needed. METHODS: We randomly assigned 870 patients who had resected stage III melanoma with BRAF V600E or V600K mutations to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos. The primary end point was relapse-free survival. Here, we report 5-year results for relapse-free survival and survival without distant metastasis as the site of the first relapse. Overall survival was not analyzed, since the required number of events to trigger the final overall survival analysis had not been reached. RESULTS: The minimum duration of follow-up was 59 months (median patient follow-up, 60 months for dabrafenib plus trametinib and 58 months for placebo). At 5 years, the percentage of patients who were alive without relapse was 5295CI], 48 to 58) with dabrafenib plus trametinib and 3695 32 to 41) with placebo (hazard ratio for relapse or death, 0.51; 95 0.42 to 0.61). The percentage of patients who were alive without distant metastasis was 6595 61 to 71) with dabrafenib plus trametinib and 5495 49 to 60) with placebo (hazard ratio for distant metastasis or death, 0.55; 95 0.44 to 0.70). No clinically meaningful between-group difference in the incidence or severity of serious adverse events was reported during the follow-up period. CONCLUSIONS: In the 5-year follow-up of a phase 3 trial involving patients who had resected stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-term toxic effects. (Funded by GlaxoSmithKline and Novartis; COMBI-AD ClinicalTrials.gov number, NCT01682083; EudraCT number, 2012-001266-15.).
AB - BACKGROUND: In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations. To confirm the stability of the relapse-free survival benefit, longer-term data were needed. METHODS: We randomly assigned 870 patients who had resected stage III melanoma with BRAF V600E or V600K mutations to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos. The primary end point was relapse-free survival. Here, we report 5-year results for relapse-free survival and survival without distant metastasis as the site of the first relapse. Overall survival was not analyzed, since the required number of events to trigger the final overall survival analysis had not been reached. RESULTS: The minimum duration of follow-up was 59 months (median patient follow-up, 60 months for dabrafenib plus trametinib and 58 months for placebo). At 5 years, the percentage of patients who were alive without relapse was 5295CI], 48 to 58) with dabrafenib plus trametinib and 3695 32 to 41) with placebo (hazard ratio for relapse or death, 0.51; 95 0.42 to 0.61). The percentage of patients who were alive without distant metastasis was 6595 61 to 71) with dabrafenib plus trametinib and 5495 49 to 60) with placebo (hazard ratio for distant metastasis or death, 0.55; 95 0.44 to 0.70). No clinically meaningful between-group difference in the incidence or severity of serious adverse events was reported during the follow-up period. CONCLUSIONS: In the 5-year follow-up of a phase 3 trial involving patients who had resected stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-term toxic effects. (Funded by GlaxoSmithKline and Novartis; COMBI-AD ClinicalTrials.gov number, NCT01682083; EudraCT number, 2012-001266-15.).
M3 - Article
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 12
ER -